Phase 1/2Active, not recruiting
RTX001 Autologous Engineered Macrophages for Liver Cirrhosis (EMERALD)
An Open-label Phase 1/2 Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of RTX001 Autologous Macrophages in Participants With Liver Cirrhosis Who Have Hepatic Decompensation (EMERALD)
- Sponsor
- Resolution Therapeutics Limited (Research network)
- Enrolment
- 30 planned
- Conditions
- End-stage Liver Disease (ESLD); Cirrhosis, Liver; Cirrhosis, Decompensated; Liver Diseases; Fibrosis and Cirrhosis of Liver; Decompensated Liver Cirrhosis; Decompensated Cirrhosis; Steatotic Liver Disease
- Interventions
- RTX001
- Ages
- adults, older adults
- Registry
- NCT06823713
From the registry
The purpose of this study is to assess the safety and efficacy of RTX001 in patients with end-stage liver disease. This study is the first time RTX001, a macrophage cell therapy engineered to have an anti-inflammatory and anti-fibrotic effect, will be given to humans.
Primary outcomes
- Safety and Tolerability